Eli Lilly reported early phase 1 clinical data for its gene-editing therapy VERV-102, acquired from Verve Therapeutics in a $1 billion deal, showing a 62% cholesterol reduction at a high dose in treated participants. Lilly positioned the one-time approach as a potential way to lower LDL and reduce heart-disease risk at scale. Company updates emphasized the absence of treatment-related serious adverse events in the Phase 1 study, a point underscoring improvements from an earlier Verve program that was shelved over safety concerns. The report frames the results as an early proof point rather than a definitive efficacy readout. If later studies confirm durability and clinical benefit, the program would add a gene-editing option to a crowded LDL-lowering landscape dominated by chronic dosing. Lilly’s update also highlights the company’s growing push to leverage its acquired gene-editing platform across cardiovascular indications.